Big Board

Content Ideas
Result Content Idea Research
Result Content Idea Research
1 First-ever phase 3 clinical trial opens for patients with advanced anal cancer
2 Patients with Head and Neck Cancer See Impact on Ability to Work Due to Radiotherapy
3 First-ever phase 3 advanced anal cancer trial opens for patient enrollment
4 Nutritional Index, ECOG Performance Status Indicative of Prognosis for Patients With Gastric And Esophageal Adenocarcinoma
5 Potential New Option in Aggressive, Ultra Rare Sarcoma
6 RV001 Granted FDA Fast Track Designation for Treatment of Prostate Cancer
7 Novel Agent ADP-A2M4 Elicits Durable Response in Synovial Sarcoma
8 Adagrasib Shows Promise in Phase 1/2 Trial for KRAS G12C Mutated NSCLC, CRC, and Other Solid Tumors
9 A new way to plug a human brain into a computer: Via veins
10 Three-Drug Combos May Overcome Targeted Therapy Resistance in Melanoma
11 ASCO Systemic Therapy Guideline Developed for Advanced HCC
12 ECOG performance status ≥ 2 as a prognostic factor in patients with advanced non small cell lung cancer treated with immune checkpoint inhibitors—A systematic review and meta-analysis of real world data
13 Understanding clinical practice and survival outcomes in patients with unresectable stage III non-small-cell lung cancer in a single centre in Quebec
14 Dr. Leal on the Rationale for the ECOG-ACRIN EA5161 Trial in ES-SCLC
15 Randomized Clinical Trial of Pembrolizumab Versus Chemotherapy for Previously Untreated Chinese Patients With PD-L1-Positive Locally Advanced or Metastatic Non-Small-Cell Lung Cancer: KEYNOTE-042 China Study
16 ECOG-ACRIN research at ASCO 2020
17 An Italian, multicenter, real-world, retrospective study of first-line pazopanib in unselected metastatic r...
18 BTKi-Containing Triplet Active in Relapsed/Untreated Mantle Cell Lymphoma
19 Genomic study of 6000 NCI-MATCH cancer patients leads to new clinical trial benchmarks
20 First 'Plug and Play' Brain Prosthesis Demonstrated in Paralyzed Person
21 BRIEF-ECOG-ACRIN Provides Syndax With Results Of Phase 3 E2112 Trial Of Entinostat Plus Exemestane For HR+, HER2- Breast Cancer
22 Lenvatinib Combo Shows Promising Findings in Phase 2 Study of Non-Clear Cell Renal Cell Carcinoma
23 Biomarker for Immune Response Identified in Relapsed/Refractory DLBCL
24 ECOG-ACRIN Provides Syndax Pharmaceuticals With Results of Phase 3 E2112 Trial of Entinostat Plus Exemestane in Patients with HR+, HER2- Breast Cancer
25 Al Benson named to new role in ECOG-ACRIN leadership
26 AIVITA Biomedical's Phase 2 Glioblastoma Trial Shows Improved Progression Free Survival | Vaccines | News Channels
27 Imetelstat Shows Durable Efficacy in Relapsed/Refractory Low-Risk MDS
28 Pembrolizumab, nadofaragene firadenovec lead the charge in BCG-unresponsive NMIBC
29 SIENDO Trial of Selinexor in Endometrial Cancer Gets Green Light to Continue
30 Two rival theories of consciousness are put to the test
31 Nerve Monitoring System Market Size, Share, Trends & Forecast 2020-2028
32 Risk Factors for Poor Prognosis in Patients With Cancer and COVID-19
33 Treatment Options for Frontline CLL Merit In-depth Patient Discussions
34 Determining if Tumor Gene Testing Can Select Efficacious Precision Cancer Treatments
35 Study Finds No Benefit to Surgery, Radiation in De Novo Stage IV Breast Cancer
36 E1912 follow-up shows ibrutinib effective, well tolerated by majority of CLL patients
37 Sintilimab/Bevacizumab Biosimilar Combo Shows Superior OS, PFS Over Sorafenib in Advanced Unresectable HCC
38 Immutep's Phase II TACTI-002 Study Reports Encouraging Data at SITC
39 Partner Therapeutics Announces Start of Phase 3 Portion of Clinical Study of Leukine® in Combination with Ipilumimab and Nivolumab in Front Line Treatment of Melanoma
40 Mitch Schnall: “We don't want to lose momentum as this review is happening”
41 NCI Trials for Oct. 2020
42 Tebentafusp Improves OS in Frontline Metastatic Uveal Melanoma
43 Anal cancer's first randomized trial for inoperable disease sets the treatment standard
44 Surgery and radiation do not extend survival in newly diagnosed metastatic breast cancer
45 NCI Trials for May 2020
46 E1912 trial leads to FDA approval of ibrutinib-rituximab combo for untreated CLL
47 Clinical Factors Predict Deterioration Among Patients With Cancer, COVID-19
48 Sugemalimab/Chemo Combo Elicits Clinically Meaningful PFS Benefit in Metastatic NSCLC
49 COVID-19 in Cancer Patients: What Do We Know?
50 NCTN group chairs: Cancer trials take backseat to clinical care amid COVID-19 pandemic
51 Immunotherapy Should Not Be Withheld Because of Sex, Age, or PS
52 Metastatic Pancreatic Cancer Guidelines (ASCO, 2020)
53 No OS Benefit After Addition of Early Locoregional Therapy to Optimal Systemic Therapy in the Setting of De Novo Metastatic Breast Cancer
54 Sotorasib Displays Disease Control, Safety in KRAS G12C–Mutant Gastrointestinal Cancers
55 Abbreviated MRI outperforms 3D mammograms at finding cancer in dense breasts
56 Carfilzomib does not improve outcomes in newly diagnosed myeloma compared to bortezomib
57 Outcomes of Larotrectinib by Prior Therapy and Performance Status in TRK Fusion Cancer
58 Janssen Receives CHMP Positive Opinion for Expanded Use of IMBRUVICA® (ibrutinib) in Combination with Rituximab for Previously Untreated Patients with Chronic Lymphocytic Leukaemia (CLL)
59 Advantages of Deep Learning for ECoG-based Speech... : The Hearing Journal
60 NCI-MATCH: T-DM1 shows promising activity in salivary gland cancer
61 Cancer Therapy Leukemia Instrument Shows Promise for AML Clinical Trials
62 G1 Therapeutics: Depressed Price Before Catalyst, No Apparent Reason
63 Breast cancer patients with government insurance at higher risk of death
64 Nivolumab Approved in Europe for Advanced Esophageal Cancer
65 Ripretinib Shows Antitumor Activity in Fourth-Line KIT/PDGFRA-Mutated Advanced GIST
66 NCI Trials for August 2020
67 TAILORx dispels chemo-brain notion: Women on hormone therapy also report cognitive decline
68 O'Dwyer Elected ECOG-ACRIN Group Co-Chair, Succeeds Comis
69 Determining Quality of Life in Patients with Advanced Cancer
70 Progressing malignancy linked to higher mortality among patients with cancer and COVID-19
71 Active Cancer Increases Death Risk in Patients With COVID-19
72 Janssen Seeks Expanded Use of IMBRUVICA® (ibrutinib) in Combination with Rituximab for Patients with Previously Untreated Chronic Lymphocytic Leukaemia (CLL)
73 'Plug And Play' Brain Prosthesis Debuts In Paralyzed Person
74 Abbreviated MRI Outperforms 3-D Mammograms at Finding Cancer in Dense Breasts
75 COVID-19 Delays FDA Review of Liso-Cel for Relapsed/Refractory Large B-Cell Lymphoma
76 FDA approves IMBRUVICA® (ibrutinib) for treatment of CLL and SLL
77 Electrocorticography Implant for Plug and Play Brain-Computer Control
78 Robert Comis, piano man, clinical trials impresario, and ECOG-ACRIN co-chair, dies unexpectedly at 71
79 Hydroxychloroquine, Azithromycin Combo Risky for Cancer Patients
80 Elevated Dose of Osimertinib Induced Clinical Activity in EGFR Exon 20-Mutant NSCLC
81 Frontline Nivolumab/Ipilimumab Shows Clinical Benefit in NSCLC With Poor Prognosis
82 Novel Algorithm Proposed for Sensory Event Detection via Flexible Film Electrodes
83 Simple Tool Predicts Survival in Advanced Cancer
84 FDA Issues Clinical Hold on CAR-T Cell Trial for Patients With Myeloma
85 Addition of Evolocumab to Maximally Tolerated Statin Therapy Not Found to Affect Cognition
86 AI Translates Human Brain Signals to Text
87 A brain implant in paralysed person helps control computer cursor
89 Paralyzed Patient Controls Computer Using Brain With Plug & Play System
90 Nerve Monitoring System Market Provides In-Depth Analysis of the Industry, With Current Trends and Future Estimations to Elucidate The Investment Pockets | (2020-2027)
91 No Short-Term Cognitive Harm From Low LDL-C Levels Achieved With Evolocumab
92 Trial validates a less intense treatment for HPV+ throat cancer
93 AUA 2018: Phase II Trial of Neoadjuvant Chemotherapy Followed by Extirpative Surgery for Patients with High...
94 Durvalumab-Tremelimumab Plus Chemotherapy Failed to Improve Survival in Pancreatic Cancer Subtype
95 Comprehensive Report on Nerve Monitoring Devices Market 2020 | Size, Growth, Demand, Opportunities & Forecast To 2026 | Cadwell Laboratories, Electrical Geodesics Inc., Natus Medical Inc., Neurosign Surgical, NuVasive
96 Janssen gets CHMP positive opinion for expanded use of IMBRUVICA, rituximab combo in CLL
97 Phase 3 PROSPER RCC Trial to Evaluate Neoadjuvant/Adjuvant Immunotherapy in Nonmetastatic RCC
98 Stable recordings enable 'plug-and-play' control of brain–computer interface
99 Incorporating PROs Can Improve Patient Care and Outcomes in Oncology
100 Immunotherapy-Based Triplet Is Active in HER2+ Esophagogastric Cancer